Niels Buchmann1, Benjamin Kläsner2, Jens Gempt3, Jan Stefan Bauer4, Thomas Pyka5, Claire Delbridge6, Bernhard Meyer3, Bernd Joachim Krause7, Florian Ringel3. 1. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, München, Germany. Electronic address: niels.buchmann@tum.de. 2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, München, Germany; Department of Nuclear Medicine, Klinikum Konstanz, Konstanz, Germany. 3. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, München, Germany. 4. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, München, Germany. 5. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, München, Germany. 6. Division of Neuropathology, Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, München, Germany. 7. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, München, Germany; Department of Nuclear Medicine, Universitätsklinikum Rostock, Rostock, Germany.
Abstract
OBJECTIVE: Complete resection of contrast-enhancing tumor is an important prognostic factor in glioblastoma therapy. The current clinical standard for control of resection is magnetic resonance imaging (MRI). (18)F-Fluoroethyl-l-thyrosine (FET) is a positron emission tomography (PET) radiopharmaceutical applicable for widespread use because of its long half-life radionuclide. We assessed the sensitivity of postoperative MRI versus FET-PET to detect residual tumor and the impact of the time interval between resection and FET-PET. METHODS: MRI and FET-PET were performed preoperatively and postoperatively in 62 patients undergoing 63 operations. FET-PET was performed in 43 cases within 72 hours after resection and in 20 cases >72 hours after resection. Detection and measurement of volume of residual tumors were compared. Correlations between residual tumor detection and timing of PET after resection and recurrence were examined. RESULTS: Complete resection was confirmed by both imaging modalities in 44% of cases, and residual tumor was detected consistently in 37% of cases. FET-PET detected residual tumor in 14% of cases in which MRI showed no residual tumor. MRI showed residual tumors in 5% of cases that were not identified by PET. Average PET-based residual tumor volume was higher than MRI-based volume (3.99 cm(3) vs. 1.59 cm(3)). Detection of and difference in volume of residual tumor were not correlated with timing of PET after resection or recurrence status. CONCLUSIONS: Postoperative FET-PET revealed residual tumor with higher sensitivity than MRI and showed larger tumor volumes. In this series, performing PET >72 hours after resection did not influence the results of PET. We recommend FET-PET as a helpful adjunct in addition to MRI for postoperative assessment of residual tumor.
OBJECTIVE: Complete resection of contrast-enhancing tumor is an important prognostic factor in glioblastoma therapy. The current clinical standard for control of resection is magnetic resonance imaging (MRI). (18)F-Fluoroethyl-l-thyrosine (FET) is a positron emission tomography (PET) radiopharmaceutical applicable for widespread use because of its long half-life radionuclide. We assessed the sensitivity of postoperative MRI versus FET-PET to detect residual tumor and the impact of the time interval between resection and FET-PET. METHODS: MRI and FET-PET were performed preoperatively and postoperatively in 62 patients undergoing 63 operations. FET-PET was performed in 43 cases within 72 hours after resection and in 20 cases >72 hours after resection. Detection and measurement of volume of residual tumors were compared. Correlations between residual tumor detection and timing of PET after resection and recurrence were examined. RESULTS: Complete resection was confirmed by both imaging modalities in 44% of cases, and residual tumor was detected consistently in 37% of cases. FET-PET detected residual tumor in 14% of cases in which MRI showed no residual tumor. MRI showed residual tumors in 5% of cases that were not identified by PET. Average PET-based residual tumor volume was higher than MRI-based volume (3.99 cm(3) vs. 1.59 cm(3)). Detection of and difference in volume of residual tumor were not correlated with timing of PET after resection or recurrence status. CONCLUSIONS: Postoperative FET-PET revealed residual tumor with higher sensitivity than MRI and showed larger tumor volumes. In this series, performing PET >72 hours after resection did not influence the results of PET. We recommend FET-PET as a helpful adjunct in addition to MRI for postoperative assessment of residual tumor.
Authors: Peter Baumgarten; Johanna Quick-Weller; Florian Gessler; Marlies Wagner; Julia Tichy; Marie-Therese Forster; Christian Foerch; Volker Seifert; Michel Mittelbronn; Christian Senft Journal: J Neurooncol Date: 2018-05-24 Impact factor: 4.130
Authors: Claes N Ladefoged; Flemming L Andersen; Andreas Kjær; Liselotte Højgaard; Ian Law Journal: Front Neurosci Date: 2017-08-11 Impact factor: 4.677
Authors: Jonas Ort; Hussam Aldin Hamou; Julius M Kernbach; Karlijn Hakvoort; Christian Blume; Philipp Lohmann; Norbert Galldiks; Dieter Henrik Heiland; Felix M Mottaghy; Hans Clusmann; Georg Neuloh; Karl-Josef Langen; Daniel Delev Journal: J Neurooncol Date: 2021-10-01 Impact factor: 4.130
Authors: David Kis; Laszlo Szivos; Mark Rekecki; Bayan Salam Shukir; Adrienn Mate; Katalin Hideghety; Pal Barzo Journal: Front Neurosci Date: 2022-09-21 Impact factor: 5.152